EFFECT OF PHARMACOTHERAPY FOLLOW-UP TO TYPE 2 DIABETES MELLITUS PATIENTS AT A PRIMARY HEALTH CARE SERVICE IN CORDOBA (ARGENTINA)

ROSARIO

Encuentro; II Reunión Internacional de Ciencias Farmacéuticas. RICiFa 2012; 2012

FACULTAD DE CIENCIAS BIOQUÍMICAS Y FARMACEUTICAS - UNR

EFFECT OF PHARMACOTHERAPY FOLLOW-UP TO TYPE 2 DIABETES MELLITUS PATIENTS AT A PRIMARY HEALTH CARE SERVICE IN CORDOBA (ARGENTINA). Badesso RE1, Solá Uthurry NH2, Armando PD3 1Farmacia Centralizada. Dispensario N° 3 ?Ramón Carrillo?. Dirección de Salud Pública. Municipalidad de Alta Gracia. Provincia de Córdoba (Argentina). 2Fundación Pharmaceutical Care España. 3Departamento de Farmacología. Facultad de Ciencias Químicas. Universidad Nacional de Córdoba (Argentina). Introduction The pharmacist can play an important role in the pharmacotherapy follow-up (PTF) of type 2 diabetes mellitus (DM2) patients. The coordination between physicians and pharmacists is fundamental to increase adherence, improve both drug treatment and quality of life, and reduce health-related costs. Based on these premises, the aim of this study was to determine the effect of PTF in patients who belong to the City Hall Program for Early Detection of DM2 in Alta Gracia city (Córdoba, Argentina). Material and methods A longitudinal follow-up prospective study was conducted in the area of primary care, specifically in the Central Pharmacy of the Direction of Public Health (Alta Gracia City Hall). Patients who agreed to participate constituted the intervention group (IG); the rest of the patients who received standard care were included in the control group (CG). Patients with type 1 diabetes mellitus, those with insulin-requiring DM2 and pregnant women were excluded. Dáder Method for PTF and MEDAFAR Classification to record the pharmacotherapeutic referrals were used. The adherence to the pharmacologic treatment was obtained by comparing monthly drug recalls. Results The study included 101 patients: 74 belonging to the IG, and 27 to the CG. One hundred and ninety eight pharmaceutical interventions (PI) were performed; from which 118 PI were Pharmacist-Patient type (72.9% resolved). On the other hand, 80 PI were Pharmacist-Patient-Physician type (73.2% resolved). The initial fasting glycaemia averaged 157.0 mg% in the IG and 135,0 mg% in the CG; at the end of the study, the values were modified to 110.0 mg% and 174.0 mg% respectively leading to a 29.9% decrease of fasting glycaemia in the IG, and to a 28.9% increase in the CG. The main Drug Related Problem (DRP) that caused the Negative Outcomes associated with Medication (NOMs) was the insufficiently treated medical conditions (41.3%). Most of the pharmacotherapeutic referrals were information ones (59.0%). The adherence to pharmacologic treatment in the IG was enlarged about 27.0%. Conclusions The PTF to DM2 patients allowed a high resolution of NOMs, increased the adherence of patients to the pharmacologic treatment, and an adequate coordination between practitioners by the use of the MEDAFAR Classification. References: 1)Murillo MD, Fernandez-Llinos F, Tuneus Valls L. Guía de Seguimiento Farmacoterapéutico sobre Diabetes. Universidad de Granada. Grupo de Investigación en Atención Farmacéutica; 2004. 2)Pérez Ballester T, González Pérez R, Rius Chaves C, Martín Calero MJ. Incidencia del seguimiento farmacoterapéutico en pacientes diabéticos. Seguim Farmacoter 2004; 2(4): 228-234. 3)Machado Alba JE, Torres-Rodriguez S, Vallejos-Narváez A. Efectividad del seguimiento farmacoterapéutico en diabéticos tipo 2. Colomb. méd. 2011;42(1):72-80. 4)Sánchez RP, Gómez Escolar CA, Álvarez de Toledo Saavedra F, Fernández de Cano Martín N, Solá Uthurry N.Clasificación de Derivaciones Fármaco-terapéuticas Medafar. Madrid: Fundación Pharmaceutical Care España; SEMERGEN; 2008. 5)Machuca M, Fernández -Limós F, Faus MJ. Método Dáder. Guía de Seguimiento Farmacoterapéutico. Grupo de Investigación en Atención Farmacéutica. Granada; 2003. 6)Rodriguez Chamorro MÁ, García-Gimenez E, Busquets Gil A, Rodriguez Chamorro A, Pérez Merino EM, Faus Dáder EM, Martínez Martínez F.. Herramientas para identificar el cumplimiento farmacoterapéutico desde la farmacia comunitaria. Pharmaceutical Care España 2009; 11(4):183-191.